OSA - 医索

Amivantamab plus lazertinib vs osimertinib infirst-line EGFR-mutant advanced non-small cell lungcancer(NSCLC)with biomarkers of high-risk diseaseA secondary analysis from the phase 3 MARIPOSA study

医客学院 - 会议报告集

Nivolumab plus ipilimumab vs chemotherapy as first-linetreatment for microsatellite instability-highmismatchrepairdeficient metastatic colorectal cancer expandedefficacy analysis from CheckMate 8HW

医客学院 - 会议报告集

Neoadjuvant treatment of lBl310 (anti-CTLA-4 antibody) plus sintilimab(anti-PD.1 antibody) in patients with microsatellite instabilityhighmismatchrepair-deficient colon cancer Results from a randomiz

医客学院 - 会议报告集

IO in NSCLC are there differences between the PD-(L)1 inhibitors （ROSARIO）

医客学院 - 会议报告集

MARIPOSA_ phase 3 study of first-line amivantamab lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

医客学院 - 小知识汇总

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer an open-label, single-arm, phase II trial

医客学院 - 药物研究

知名教授1年申请4项“国自然”，被通报学术不端！曾获价值超1亿元巨额资助！

根据美国政府监管机构通报：罗莎琳德富兰克林医科大学 (Rosalind Franklin University of Medicine and Science，RFUMS)癌症细胞生物学、免疫学和感染中心的前主任何江林（Johnny J. He）教授在向美国国立卫生研究院(NIH)提交的四项基金.....

学术资讯 - 科研诚信事件

The influence of procedural volume on the outcome of endoscopic submucosal dissection for gastric neoplasm A nationwide population-b

医客学院 - 会议报告集

Colorectal endoscopic submucosal dissection using a concealable robotic add-on device A comparative in vivo feasibility study

医客学院 - 会议报告集

A Multicenter, Randomized Phase II Study of TNT With FOLFIRINOX and SBRT, with or without Losartan (L) and Nivolumab (N) in Borderli

医客学院 - 会议报告集